Summit Therapeutics opens Phase II trial of ivonescimab regimens in advanced kidney cancer

• Summit Therapeutics opened a global Phase II trial of ivonescimab-based treatments for previously untreated advanced clear cell kidney cancer.
• The study, conducted with Akeso, plans to enroll approximately 100 patients in the U.S. and China.
• Researchers will assess safety and efficacy of ivonescimab alone or in combinations against standard-of-care nivolumab with ipilimumab.
• The trial expands ivonescimab’s development beyond lung cancer into additional tumor types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019470671) on October 19, 2026, and is solely responsible for the information contained therein.